Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and provided a business update.
Covered in this story
Call it yourself
No calls on $CLLS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Cellectis →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.